Share buy-back programme – transactions April
Company announcement
Gabriel Holding A/S
Share buy-back programme – transactions April
On 16 March 2026, Gabriel Holding A/S initiated a share buy-back programme. The share buy-back programme runs from and including 16 March 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital or for an amount up to DKK 20 million.
The share buy-back programme is carried out without application of the Safe Harbour rules in Article 5 of the Market Abuse Regulation, e.g. due to the current limited liquidity in the company’s share. The shares will be repurchased at market price and in accordance with the general meeting authorization and within the framework of the Market Abuse Regulation.
The following transactions have been carried out under this programme:
| Number of shares | Average purchase price | Transaction value in DKK | |
| Accumulated share of the programme, latest announcement | 1,056 | 212.29 | 224,176 |
| April 2026 | 51,378 | 228.74 | 11,752,433 |
| Accumulated under the programme | 52,434 | 228.41 | 11,976,609 |
| Gabriel total shares | 1,890,000 | ||
| Gabriel treasury shares | 52,434 | 2.77% | of the share capital |
Enquiries and further information: CEO Anders Hedegaard Petersen, phone: +45 9630 3117
This is a translation of the original Danish text. In the event of discrepancies between the Danish and English texts, the Danish version shall prevail.
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AEVEX Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against AEVEX Corp. - AVEX
- Rogers Communications Inc. Announces Pricing of Public Offering of US$1 billion Fixed-to-Fixed Rate Subordinated Notes and Canadian Private Placement of Cdn$600 million Fixed-to-Fixed Rate Subordinate
- Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share